2. Academic Validation
  3. Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020

Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020

  • Asia Pac J Ophthalmol (Phila). 2020 May-Jun;9(3):250-259. doi: 10.1097/APO.0000000000000291.
Anindya Samanta 1,  Aamir A Aziz 2,  Mahima Jhingan 3,  Sumit Randhir Singh 3,  Arshad M Khanani 2 4,  Jay Chhablani 5
Affiliations

Affiliations

  • 1 Department of Medicine, Allegheny Health Network, Pittsburgh, PA.
  • 2 Sierra Eye Associates, Reno, NV.
  • 3 Jacobs Retina Center at Shiley Eye Center, University of California, San Diego, La Jolla, CA.
  • 4 University of Nevada, Reno, NV.
  • 5 Department of Ophthalmology, University of Pittsburgh Eye and Ear Institute, Pittsburgh, PA.
PMID: 32511123 DOI: 10.1097/APO.0000000000000291
Abstract

Age-related macular degeneration (AMD) is one of the most common causes of vision loss. Advanced forms of AMD are seen in primarily 2 types-neovascular AMD (nAMD) with the presence of choroid neovascularization and nonneovascular AMD (nnAMD) with geographic atrophy. Although there are 4 anti-vascular endothelial growth factor drugs either widely used or approved for the former, there are no current treatments for the latter. This review will highlight upcoming treatments for AMD currently in clinical trials. For nAMD: Abicipar pegol, an intravitreal anti-vascular endothelial growth factor based on designed ankyrin repeat proteins (DARP) in protein, is currently pending approval. Conbercept and Faricimab, 2 intravitreal anti-growth factors, are currently in phase 3. Nine other upcoming agents have at least produced results in the 2A phase including intravitreal injections (KSI-301, OPT-302, RGX-314, ICON-1, and DE-122), depot (GB-102), drug reservoir (PDS), topical drops (PAN-90806), and oral formulations (AKST4290). We summarize all the newer molecules.

Figures
Products